Jose Karam
Overview
Explore the profile of Jose Karam including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
124
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jammihal T, Saliby R, Labaki C, Soulati H, Gallegos J, Peris A, et al.
Nat Cancer
. 2025 Jan;
6(2):372-384.
PMID: 39789182
Immune checkpoint inhibitors can lead to 'exceptional', durable responses in a subset of persons. However, the molecular basis of exceptional response (ER) to immunotherapy in metastatic clear cell renal cell...
2.
Marconi L, de Bruijn R, van Werkhoven E, Beisland C, Fife K, Heidenreich A, et al.
World J Urol
. 2018 Aug;
36(12):1973-1980.
PMID: 30069581
Introduction: Recent trials have emphasized the importance of a precise patient selection for cytoreductive nephrectomy (CN). In 2013, a nomogram was developed for pre- and postoperative prediction of the probability...
3.
Biebighauser K, Gao J, Rao P, Landon G, Pagliaro L, Dinney C, et al.
Asian J Urol
. 2017 Dec;
4(2):124-127.
PMID: 29264217
Bone metastasis of non-seminomatous germ cell tumors (NSGCT) of the testes is a rare event and even more uncommon at initial presentation. Generally, bone lesions are discovered in the presence...
4.
DAndrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, et al.
Eur Urol Focus
. 2017 Jul;
5(1):97-103.
PMID: 28753840
Background: Improvement in postoperative risk stratification of upper tract urothelial carcinoma (UTUC) is required to better predict outcomes and counsel patients on adjuvant treatment. Objective: To validate the association between...
5.
Wang Z, Kim T, Peng B, Karam J, Creighton C, Joon A, et al.
Clin Cancer Res
. 2017 Jul;
23(21):6686-6696.
PMID: 28710314
Sarcomatoid renal cell carcinoma (SRCC) ranks among the most aggressive clinicopathologic phenotypes of RCC. However, the paucity of high-quality, genome-wide molecular examinations of SRCC has hindered our understanding of this...
6.
Koh M, Nguyen V, Lemos Jr R, Darnay B, Kiriakova G, Abdelmelek M, et al.
Cancer Res
. 2014 Nov;
75(2):316-29.
PMID: 25421578
Clear-cell renal cell cancer (CRCC) is initiated typically by loss of the tumor-suppressor VHL, driving constitutive activation of hypoxia-inducible factor-1 (HIF1) and HIF2. However, whereas HIF1 has a tumor-suppressor role,...
7.
Abel E, Carrasco A, Karam J, Tamboli P, Delacroix S, Vaporciyan A, et al.
BJU Int
. 2013 Oct;
114(5):667-73.
PMID: 24128265
Objective: To evaluate the impact of microscopically positive vascular margins on recurrence and cancer-specific survival (CSS) in patients with renal cell carcinoma (RCC) with venous thrombus Patients And Methods: We...
8.
Svatek R, Karam J, Karakiewicz P, Gallina A, Casella R, Roehrborn C, et al.
J Urol
. 2007 Dec;
179(2):478-84.
PMID: 18076936
Purpose: We tested the hypothesis that urinary cathepsin B and L are associated with bladder cancer recurrence and invasiveness in patients with a history of nonmuscle invasive urothelial carcinoma of...
9.
Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh J
Urol Oncol
. 2006 Mar;
24(2):152-60.
PMID: 16520279
Prostate cancer and transitional cell carcinoma (TCC) of bladder are the 2 most common malignancies in the male adult urogenital system. Epigenetic gene silencing, particularly tumor suppressor genes, has become...
10.
Svatek R, Karakiewicz P, Shulman M, Karam J, Perrotte P, Benaim E
Eur Urol
. 2006 Jan;
49(4):666-74.
PMID: 16423446
Objective: Our objective was to develop a nomogram that predicts the probability of cancer-specific survival in men with untreated androgen-independent prostate cancer (AIPC). Methods: AIPC was diagnosed in 129 consecutive...